? Immunobiology Program The Immunobiology Program (IMB) serves as a rich resource for the Abramson Cancer Center (ACC) in advancing an understanding of immunobiology and immunotherapy of cancer. The Program aims to: 1) Understand the fundamental aspects of immune biology, including leukocyte activation, differentiation, inactivation, and transformation as these relate to cancer; 2) Forge a comprehensive understanding of tumor immune surveillance using state-of-the art in vitro, animal model, and human experimental systems; and 3) Guide translation of novel clinical strategies for immunotherapy of cancer by leading or collaborating on human clinical trials. Established in 1974, this Research Program received ?Exceptional? merit at the time of the last CCSG renewal application. The Program co-Leaders (PLs) are Warren Pear, MD, PhD, an expert in the molecular biology of leukocyte development and malignant transformation and E. John Wherry, PhD, a leader in tumor immunology, immune exhaustion and immunotherapy. Drs. Pear and Wherry are experienced, NCI- funded investigators who are highly collaborative and whose research interests span the realm of basic and translational science. There are 39 Program members from nine departments and three schools with long- standing intra- and inter-Programmatic collaborations spanning the basic, clinical, and population science Programs. Members include international leaders in basic immunology, tumor immunobiology and translational immunotherapy who have driven landmark breakthroughs such as molecularly defining T cell exhaustion, dissecting the biologic response to checkpoint inhibition, and developing CAR T cells that revolutionized cellular therapy for cancer. IMB collaborates extensively with other Programs for clinical translation and biomarker discovery. For example, CART19 T cells were designed in IMB then translated to the clinic with members of the Hematologic Malignancies and Pediatric Oncology Programs in studies that led to two FDA- approved indications. The PLs facilitate interactions through multiple weekly seminars and meetings, promotion of collaborative grants and projects, two annual research retreats, pilot project grants, and training programs. During the current project period, PLs recruited 11 new Full members, expanded important forums, facilitated new collaborative grants, initiated new ACC-wide initiatives, and were actively involved in decisions regarding new and existing Shared Resources. Currently, Program members have $24.2M in research grant funding (annual direct costs), of which $15.1M is peer-reviewed and $4.1M is NCI-funded. The Program holds 38 R01-equivalents. During the current project period, Program members published 468 cancer-related publications, many of which are in top journals in the field. Of these, 19% are intra-Programmatic, 32% are inter-Programmatic, and 72% are multi-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088742
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications